Abstract:Cisplatin resistance in tumor cells is known mainly due to the reduced accumulation of platinum ions by efflux, detoxification by intracellular GSH, and nucleotide excision repair machinery-mediated nuclear DNA repair. In this work, theranostic Pt(IV)-NPs, which are precisely self-assembled by biotin-labeled Pt(IV) prodrug derivative and cyclodextrin-functionalized IR780 in a 1:1 molecular ratio, have been developed for addressing all these hurdles via mitochondria-targeted chemotherapy solely or chemophotothermal therapy. In these nanoparticles, IR780 as a small-molecule dye acts as a mitochondria-targeting ligand to make Pt(IV)-NPs relocate finally in the mitochondria and release cisplatin. As demonstrated by in vitro and in vivo experiments, Pt(IV)-NPs can markedly facilitate cancer-specific mitochondrial targeting, inducing mitochondrial dysfunction and mitochondrial DNA (mtDNA) damage, thus greatly increasing the Pt accumulation, reducing the GSH levels, and avoiding DNA repair machinery in cisplatin-resistant cancer cells (A549R), finally resulting in significant inhibition of A549R tumor growth on animal models by chemotherapy solely. Upon near-infrared irradiation, mitochondria-targeted chemophotothermal synergistic therapy can be realized, further overcoming cisplatin resistance and even eliminating A549R tumors completely. Moreover, such novel Pt(IV)-NPs integrate multimodal targeting (cancer and mitochondria targeting), imaging (near-infrared imaging and photoacoustic imaging), and therapeutic (chemo- and photothermal therapy) moieties in a constant ratio (1:1:1) into a single, reproducible, and structurally homogeneous entity, avoiding nonuniform drug loading and premature leakage as well as the discrete steps of imaging and therapy, which thus is more beneficial for precise therapeutics and future clinical translation.

Mitochondria-Targeted Multifunctional Nanoprodrugs by Inhibiting Metabolic Reprogramming for Combating Cisplatin-Resistant Lung Cancer

Nanoparticle Delivery of a Triple-Action Pt(iv) Prodrug to Overcome Cisplatin Resistance Via Synergistic Effect

Delivery of Platinum (II) Drugs with Bulky Ligands in Trans-Geometry for Overcoming Cisplatin Drug Resistance.

Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy

Mitochondria-Targeted Mesoporous Organic Silica Nanoplatforms for Overcoming Cisplatin Resistance by Disturbing Mitochondrial Redox Homeostasis

Targeting the Mitochondria with Pseudo- Stealthy Nanotaxanes to Impair Mitochondrial Biogenesis for Effective Cancer Treatment

Mitochondria-targeted nanoparticles overcome chemoresistance via downregulating BACH1/CD47 axis in ovarian carcinoma

Dual Aptamer Modified Dendrigraft Poly-L-lysine Nanoparticles for Overcoming Multi-Drug Resistance Through Mitochondrial Targeting.

Peptide-Based Autophagic Gene and Cisplatin Co-delivery Systems Enable Improved Chemotherapy Resistance

Overcoming Tumor Resistance to Cisplatin by Cationic Lipid-Assisted Prodrug Nanoparticles.

Mitochondria-acting Carrier-Free Nanoplatform Self-Assembled by Α-Tocopheryl Succinate Carrying Cisplatin for Combinational Tumor Therapy

Nanodrugs based on co-delivery strategies to combat cisplatin resistance

Mitochondrial-Targeting Lonidamine-Doxorubicin Nanoparticles for Synergistic Chemotherapy to Conquer Drug Resistance.

Nanoparticles (NPs)-mediated lncMALAT1 silencing to reverse cisplatin resistance for effective hepatocellular carcinoma therapy

Self-assembled Metal-Phenolic Network Nanoparticles for Delivery of a Cisplatin Prodrug for Synergistic Chemo-Immunotherapy

Hybrid Micelles Based on Pt (IV) Polymeric Prodrug and TPGS for the Enhanced Cytotoxicity in Drug-Resistant Lung Cancer Cells

In Situ Supramolecular Self‐Assembly of Pt(IV) Prodrug to Conquer Cisplatin Resistance

Effective treatment of drug-resistant lung cancer via a nanogel capable of reactivating cisplatin and enhancing early apoptosis

NIR‐Light‐Triggered Mild‐Temperature Hyperthermia to Overcome the Cascade Cisplatin Resistance for Improved Resistant Tumor Therapy

Targeted nanomedicine in cisplatin-based cancer therapeutics

Self-Assembled Metal-Phenolic Network Nanoparticles Delivery of Cisplatin Prodrug for Synergistic Chemo-Immunotherapy